DCC4827 |
So1989 |
Novel macrophage modulator, inhibiting inflammation and M1 polarization of macrophages, restoring the balance between M1-polarized and M2-polarized macrophages in high fat diets (HFD)-induced obese mice resulting in the improvement of adipose inflammation |
|
DCC4828 |
soblidotin |
Inhibitor of tubulin polymerization, resulting in cell cycle arrest and induction of apoptosis |
|
DCC4829 |
Sobuzoxane |
Orally available active prodrug of ICRF-154, interferring with topoisomerase II activity prior to the formation of intermediate cleavable DNA-enzyme complexes during the catalytic cycle resulting in tumor cell growth inhibition |
|
DCC4830 |
Sod1-derlin-1 Inhibitor 56-20 |
Novel potent inhibitor of SOD1-Derlin-1 interaction |
|
DCC4831 |
Sod1-derlin-1 Inhibitor 56-26 |
Novel potent inhibitor of SOD1-Derlin-1 interaction |
|
DCC4832 |
Sodelglitazar |
PPARdelta receptor agonist |
|
DCC4833 |
Sodium Dehydrocholate |
Hepatoprotective and choleretic agent |
|
DCC4834 |
Sodium Oxybate |
Narcolepsy agent, being used to treat catalepse and daytime sleepiness in patients with narcolepsy |
|
DCC4835 |
Solanidine |
Natural tumor antagonistic steroidal alkaloid, inducing typical cellular apoptotic hallmarks and cell cycle blockage at S-G2/M phase, activating nuclear import of DFF-40 mediated nucleosomal disruption and cell demise |
|
DCC4836 |
Solimastat |
Novel oral, broad-spectrum matrix metalloproteinase inhibitor (MMPI), being >10-fold more active than marimastat in inhibiting the processing of cell-bound TNF-alpha |
|
DCC4837 |
Somapacitan |
Novel long-acting, reversible albumin-binding growth hormone (GH) derivative for treatment of growth hormone dificiency |
|
DCC4838 |
Somatoprim |
Unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reducing GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. |
|
DCC4839 |
Somcl-668 |
Novel potent and selective allosteric modulator of sigma-1 receptor |
|
DCC4840 |
Somcl-863 |
Novel, selective and orally bioavailable c-Met inhibitor, exhibiting antitumor activity both in vitro and in vivo |
|
DCC4841 |
Sonedenoson |
A2A adenosine receptor agonist |
|
DCC4842 |
Sophoradin |
Natural analgesic, antipyretic, anti-inflammatory, and anti-tumor agent |
|
DCC4843 |
Sophorafavanone A |
Inhibitor of constitutive and inducible STAT3 activation through the activation of SHP-2 tyrosine phosphatase |
|
DCC4844 |
Sophoraflavanone B |
Natural inhibitor of the Kv1.3 channels in a concentration-dependent manner |
|
DCC4845 |
soraphinol A |
Human norepinephrine transporter blocker |
|
DCC4846 |
sori-20041 |
DAT modulator, being unique in affecting substrate uptake without impacting efflux |
|
DCC4847 |
sori-9804 |
Novel partial inhibitor of amphetamine-induced dopamine release |
|
DCC4848 |
Sortin3 Maleate |
Sorting inhibitor, blocking Vps16 function, one protein in the class C tethering complex, and increasing aflatoxin synthesis and export |
|
DCC4849 |
Spam (signal Peptide-based Affinity Maturated Ligand) |
Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1) |
|
DCC4850 |
spb03924 |
Novel telomerase inhibitor |
|
DCC4851 |
SPB08007 |
0 |
|
DCC4852 |
Spd-2-am |
Novel photo-controllable hydrogen sulfide donor applicable in live cells |
|
DCC4853 |
Spectinamide-1599 |
Novel anti-tuberculosis agent against intracellular Mycobacterium tuberculosis |
|
DCC4854 |
Spectinomycin Dihydrochloride |
Antibiotic, binding to the bacterial 30S ribosomal subunit, interfering with the initiation of protein synthesis and with proper protein elongation and leading to bacterial cell death |
|
DCC4855 |
Spi-1865 |
Novel gamma-secretase modulator |
|
DCC4856 |
Spirohydantoin-21 |
Novel selective orally bioavailable inhibitor of p300/CBP histone acetyltransferase |
|